Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.00
- Piotroski Score 6.00
- Grade Overweight
- Symbol (FOLD)
- Company Amicus Therapeutics, Inc.
- Price $9.49
- Changes Percentage (-1.09%)
- Change -$0.11
- Day Low $9.39
- Day High $9.64
- Year High $14.57
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.50
- High Stock Price Target $19.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.49
- Trailing P/E Ratio -20.51
- Forward P/E Ratio -20.51
- P/E Growth -20.51
- Net Income $-151,584,000
Income Statement
Quarterly
Annual
Latest News of FOLD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Kingsoft Shares Jump After Profit Rises 14-Fold
Kingsoft Corp's stock surged 10% to HK$32.20 after its net profit increased 14-fold in Q3 driven by robust online gaming revenue growth....
By MarketWatch | 2 days ago -
Indian coffee chain Blue Tokai targets three-fold revenue before deciding on IPO
Blue Tokai, an Indian coffee chain, plans to increase revenue threefold by 2027. With backing from Verlinvest, the company aims to open 350 cafes in cities like Hyderabad. Despite market fluctuations,...
By Yahoo! Finance | 3 days ago -
Biden touts six-fold climate funding increase under his administration: 'A defining cause of my presidency'
President Biden highlighted the U.S.'s increased climate financing at the G20 summit in Rio, emphasizing his commitment to fighting climate change. Despite Biden's efforts, President-elect Trump plans...
By Fox News | 3 days ago
